Navigation Links
Immunomedics Announces Preclinical Therapy Results of SN-38 Immunoconjugate for Colorectal Cancer
Date:1/20/2009

SAN FRANCISCO, Jan. 20 /PRNewswire-FirstCall/ -- Immunomedics, Inc. (Nasdaq: IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that results presented at the 2009 Gastrointestinal Cancers Symposium showed that labetuzumab-SN-38, an antibody-drug conjugate, selectively delivers SN-38 to human colon carcinoma in animal models as an effective new therapy.

SN-38 is the active metabolite of irinotecan, a chemotherapeutic agent approved by the FDA for the treatment of colorectal, lung, and other cancers. Due to its toxicity and poor solubility, SN-38 cannot be administered systemically to cancer patients. The Company has previously reported that by conjugating SN-38 to antibodies, the powerful cancer drug can be delivered selectively to tumors, thereby increasing the amount reaching the tumors and minimizing damage to normal tissues and organs. (Please refer to http://www.immunomedics.com/news_pdf/2008_PDF/PR03202008.pdf).

In this study, the therapeutic efficacy of SN-38 conjugated to labetuzumab was evaluated in two animal models of human colon cancer. Labetuzumab is a non-internalizing humanized antibody that binds to the carcinoembryonic antigen (CEACAM5) expressed by many solid cancers. The Company has conducted clinical trials with the naked and radiolabeled antibody in patients with colorectal, breast and pancreas cancers.

In a lung metastatic model of colon carcinoma, therapy with labetuzumab-SN-38 conjugate increased median survival time (MST) 1.9- to 3.4-fold compared to various controls, with 20% of animals alive at the end of the study. In another colon cancer model, MST for the immunoconjugate treatment group in
'/>"/>

SOURCE Immunomedics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Modigene Announces Positive Results of Pilot Toxicity Study of Its Long-Acting Human Growth Hormone hGH-CTP
2. Kyowa Hakko Kirin Announces Development Policy for Anti-Parkinsons Disease Drug KW-6002 (Istradefylline)
3. Intra-Cellular Therapies Announces Successful Outcome of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
4. Beactica Announces Fragment-Based Drug Discovery Research Collaboration With GE Healthcare and Uppsala University
5. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
6. NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology
7. Pulmo BioTech Inc. Announces Dual Listing on Frankfurt Borse
8. Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
9. Anesiva Announces FDA Approval of Supplemental New Drug Application to Expand Zingo(TM) Indication
10. ProUroCare Medical Inc. Announces Pricing of Equity Offering
11. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... 03, 2015 Research ... addition of the "Global Craniomaxillofacial (CMF) Devices ... The global craniomaxillofacial devices market to grow ... This report covers the present and future scenario ... To calculate the market size, we use revenues ...
(Date:9/3/2015)... , Sep. 03, 2015 ... the addition of the "Diabetes Care Devices Market ... (Self-Monitoring Blood Glucose Meters, Continuous Glucose Monitors, Testing Strips, ... to 2020" report to their offering. ... be valued at USD 1.7 Billion in 2015 and ...
(Date:9/3/2015)... -- The findings of a year-long investigation conducted by NBC ... handling of its Recovery IVC filter product ... part one of the series revealed that ... fatalities, have been associated with the Recovery device. NBC ... Bard in 2004 which linked the Recovery IVC filter ...
Breaking Medicine Technology:Global Craniomaxillofacial (CMF) Devices Market 2015-2019 - Product Innovation and Cost Reduction a Key Market Trend 2The BRIC Diabetes Care Devices Market is Estimated to Grow at a CAGR of 6.3% from 2015 to 2020, to Reach USD 2.3 Billion by 2020 2The BRIC Diabetes Care Devices Market is Estimated to Grow at a CAGR of 6.3% from 2015 to 2020, to Reach USD 2.3 Billion by 2020 3IVC Filter Lawsuit News: NBC News Investigation into C.R. Bard Recovery Filters Raises Disturbing Questions, Bernstein Liebhard LLP Reports 2IVC Filter Lawsuit News: NBC News Investigation into C.R. Bard Recovery Filters Raises Disturbing Questions, Bernstein Liebhard LLP Reports 3
... Sept. 23 As technologies for fat removal become ... not only reshaping the body but also recycling the ... to the most recent statistics from the American Society ... are among the two most popular invasive and non-invasive ...
... (OTC Bulletin Board: CONX ), a worldwide developer ... year Form 10-K and reported financial results. The report disclosed ... year ended June 30, 2010. Some of the results highlighted ... for the year was $815,981 vs. $403,741 for the prior ...
Cached Medicine Technology:The New Face of Body Contouring 2Corgenix Reports Fiscal 2010 Financial Results 2Corgenix Reports Fiscal 2010 Financial Results 3
(Date:9/3/2015)... ... 03, 2015 , ... NanoCytomics LLC today announced the formation ... will bring low-cost cancer pre-screening tests to primary care physicians in the United ... platform detects and measures cellular changes at the nanoscale level. The cellular changes ...
(Date:9/3/2015)... ... September 03, 2015 , ... Mayo ... Indianapolis, have chosen Center for Hospice Care (CHC) for physician Hospice and ... at CHC as part of fulfilling their requirements for obtaining national Board Certification ...
(Date:9/3/2015)... ... ... Real Time Pain Relief (RTPR), makers of the popular rub-on pain ... an official endorsement deal with the company. Originally from New South Wales, Australia, Mason ... 15. He is an Australian bull riding champion, following in his uncles’ footsteps in ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... LANDESK Management Suite customers, as part of the LANDESK One Partner program. ... by delivering the best mobile user experience in remote access and control:, ...
(Date:9/3/2015)... City, MO (PRWEB) , ... September 03, 2015 , ... ... from NASA’s mission control, the surface of a comet, the IceCube observatory at the ... along the way. , The Fall Lecture Series for the world's foremost independently ...
Breaking Medicine News(10 mins):Health News:Preora Diagnostics to Commercialize Cancer Pre-screening Tests 2Health News:Preora Diagnostics to Commercialize Cancer Pre-screening Tests 3Health News:Physicians from Mayo Clinic and Indiana University to Complete Hospice & Palliative Medicine Training at Center for Hospice Care 2Health News:Real Time Pain Relief Sponsors the Talented PBR Bull Rider from Down Under - David Mason 2Health News:Real Time Pain Relief Sponsors the Talented PBR Bull Rider from Down Under - David Mason 3Health News:Splashtop Partners with LANDESK to Deliver High Performance Remote Access and Remote Support to and from Mobile Devices and Chromebook 2Health News:Splashtop Partners with LANDESK to Deliver High Performance Remote Access and Remote Support to and from Mobile Devices and Chromebook 3Health News:Splashtop Partners with LANDESK to Deliver High Performance Remote Access and Remote Support to and from Mobile Devices and Chromebook 4Health News:Facing the Frontiers of Science and Technology The Linda Hall Library Announces 2015 Fall Lecture Series Featuring Experiences from the South Pole to Outer Space 2Health News:Facing the Frontiers of Science and Technology The Linda Hall Library Announces 2015 Fall Lecture Series Featuring Experiences from the South Pole to Outer Space 3Health News:Facing the Frontiers of Science and Technology The Linda Hall Library Announces 2015 Fall Lecture Series Featuring Experiences from the South Pole to Outer Space 4Health News:Facing the Frontiers of Science and Technology The Linda Hall Library Announces 2015 Fall Lecture Series Featuring Experiences from the South Pole to Outer Space 5
... released by the American Heart Association, almost all women are ... a daily aspirin for them. ,In the United ... have heart disease and it is the largest single cause ... support to recommendations that exercise for at least an hour ...
... Einstein College of Medicine of Yeshiva University have discovered ... uniquely susceptible to a newly developed molecular targeted therapy. ... new therapy will be able to enroll patients who’ll ... ,The research was led by Dr. Ari Melnick, assistant ...
... haven for migratory birds, is gearing up to tackle bird ... ,"We are watching the situation closely and have ... Prabhulal Saini, Rajasthan's agriculture minister. ,"At present, ... ,Though no case of avian flu had been ...
... a bad hair day is common in our image-obsessed ... waking moment--up to 80 to 90 percent of their ... Eating Disorders Program at The Menninger Clinic in Houston. ... shape and size that is a symptom of all ...
... more than just hay fever. It occurs when the body ... IgE - to what would otherwise be harmless substances, such ... stings. In these people, their immune response overreacts by producing ... suffer. ,Although most often thought of as a ...
... Week will be celebrated May 13-19 this year. It is ... to improve their health. Women often put their health behind ... This week encourages women to be mindful of their health ... will be observed on May 15. Sponsored by the Society ...
Cached Medicine News:Health News:An Aspirin a Day Keeps Heart Disease Away 2Health News:Novel Test Identifies Leukemia Patients Likely to Respond to New Therapy 2Health News:Improving Body Image Key to Treating Eating Disorders 2Health News:Improving Body Image Key to Treating Eating Disorders 3Health News:Allergies Not Just for Children Anymore 2Health News:Women’s Health Takes the Spotlight in Ma 2
Post-Surgical compression garments...
... Albumin Cobalt Binding (ACB®) Test is a ... Albumin (IMA®) by measuring the cobalt binding ... sample. First identified in the early 1990s, ... in contact with ischemic tissue in the ...
... Albumin Cobalt Binding (ACB®) Test is a ... Albumin (IMA®) by measuring the cobalt binding ... sample. First identified in the early 1990s, ... in contact with ischemic tissue in the ...
... menu includes kits that quantitatively measure two ... (a). An elevated serum or plasma homocysteine ... and independent risk factor for cardiovascular disease. ... have associated elevated levels of Lp(a) with ...
Medicine Products: